Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293
Ulrich A. K. Betz(Bayer (Germany)), Helga Rübsamen‐Waigmann(AiCuris (Germany)), Gerald Kleymann(Bayer (Germany)), Rüdiger Fischer(Bayer (Germany)), Martin Hendrix(Bayer (Germany))
Cited by 133
Related Papers
Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes
|Science|1993|776
Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids
|Science|2003|506
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
|Nature Medicine|2002|328
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
|Oncogene|1997|326
Induction and down-regulation of PLK, a humanserine/threonine kinase expressed in proliferating cells andtumors.
|Proceedings of the National Academy of Sciences|1994|283